• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc (NQ: BEAM )

    24.48 +1.55 (+6.78%)
    Streaming Delayed Price Updated: 1:37 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Beam Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
    Beam Therapeutics' pipeline will look slimmer going forward. 
    Via The Motley Fool
    Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
    U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
    Via Benzinga
    Beam Therapeutics Stock: Bear vs. Bull
    This biotech has a few factors in its corner, but it also faces a difficult path. 
    Via The Motley Fool
    Investors Unpack Home Sales Data Ahead Of Fed Speech
    Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell. 
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    What's Going On With Beam Therapeutics Stock Thursday?
    Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Thursday. 
    Via Benzinga
    Analyst Expectations for Beam Therapeutics's Future
    Via Benzinga
    2 Cathie Wood Stocks I'm Bullish On
    These two next-gen biotechs could be outstanding buys for patient investors. 
    Via The Motley Fool
    4 Analysts Have This to Say About Beam Therapeutics
    Via Benzinga
    Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers 
    Via Benzinga
    Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
    From Beam Therapeutics
    Via GlobeNewswire
    3 Gene Editing Stocks to Generate Super-Charged Gains
    As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
    Via InvestorPlace
    1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
    Both are in a race against time to commercialize a medicine before cash runs out. 
    Via The Motley Fool
    Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
    The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
    Via The Motley Fool
    Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
    On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
    The iconic money manager has struggled the last two months. Let's see what she's buying to get back on track. 
    Via The Motley Fool
    Cathie Wood's Ark Invest Tweaks Portfolio, Sells $1.8M Worth Of DraftKings Shares
    Via Benzinga
    2 Magnificent Growth Stocks to Buy On the Dip
    It might be time to catch these falling knives. 
    Via The Motley Fool
    3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
    Cathie Wood is loading up on these healthcare stocks. 
    Via The Motley Fool
    2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
    The gene-editing market is moving fast, and it pays to get to know some of these companies. 
    Via The Motley Fool
    Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 Years
    There's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good. 
    Via The Motley Fool
    This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
    The decline of Beam's stock says little about its long-term potential, according to Wood. 
    Via The Motley Fool
    Cathie Wood's Buying These 3 Stocks Hand Over Fist
    A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
    Via The Motley Fool
    Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
    First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models 
    From Beam Therapeutics
    Via GlobeNewswire
    Cathie Wood's Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock
    Via Benzinga
    Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy
    Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic  
    Via Benzinga
    Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
    BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States 
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Participate in Upcoming September Investor Conferences
    From Beam Therapeutics
    Via GlobeNewswire
    Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
    Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and  
    Via Benzinga
    3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
    These cutting-edge biotech stocks could deliver life-changing gains for early shareholders. 
    Via The Motley Fool
    Got $200? 3 Growth Stocks to Buy That Could Double Your Money
    There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.